Fluoroquinolones in the management of community-acquired pneumonia in primary care

@article{Wispelwey2010FluoroquinolonesIT,
  title={Fluoroquinolones in the management of community-acquired pneumonia in primary care},
  author={Brian Wispelwey and Katherine R Schafer},
  journal={Expert Review of Anti-infective Therapy},
  year={2010},
  volume={8},
  pages={1259 - 1271}
}
A literature search was conducted to evaluate the pharmacokinetic and pharmacodynamic profile of the respiratory fluoroquinolones (gemifloxacin, levofloxacin and moxifloxacin) and their efficacy and safety in the management of community-acquired pneumonia (CAP). Data show that CAP is a common presentation in primary care practice, and is associated with high rates of morbidity and mortality, particularly in the elderly. Although the causative pathogens differ depending on treatment setting and… Expand
Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions
TLDR
It is reported that 1–7% of CAP cases are re-diagnosed as pulmonary TB in Asian countries, and a short-course regimen of a RFQ is still recommended for empirical therapy for CAP patients if the patient is at low risk for TB. Expand
Bacterial Infections in the Elderly Patient: Focus on Sitafloxacin
TLDR
Oral sitafloxacin is a promising therapeutic agent which merits further investigation in randomized clinical trials of elderly patients and covers broad spectrum of bacteria as compared to carbapenems, whereas in the Caucasians its use is currently limited due to the potential for ultraviolet A phototoxicity. Expand
Role of fluoroquinolones in the treatment of tuberculosis
TLDR
The aim of this review is to summarize the current status of fluoroquinolones in shortening the duration of drug-susceptible pulmonary TB and in improving the outcome of MDR-TB/XDR- TB. Expand
An Overview of Fluoroquinolones
TLDR
An overview of fluoroquinolones, their mechanism of action, their uses, resistance development and their adverse effects is given. Expand
Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
TLDR
This study determined the activity of JNJ-Q2 against a worldwide year 2010 collection of three common respiratory pathogens and demonstrated increased potency compared with other marketed fluoroquinolones that have been used to treat CABP pathogens, thus favouring further clinical development. Expand
Prevalence of and Risk Factors for Levofloxacin-Resistant E. coli Isolated from Outpatients with Urinary Tract Infection
TLDR
Levofloxacin should be prescribed cautiously in patients with these risk factors until the pathogen is identified, and the resistance rates of E. coli were high at over 25%. Expand
An Overview of Fluoroquinolones 2
22 The fluoroquinolones are broad-spectrum bactericidal agents inhibiting DNA 23 synthesis. They are active against gram positive and gram negative organisms like P. 24 aeruginosa, Mycoplasma,Expand
Is repositioning of drugs a viable alternative in the treatment of tuberculosis?
TLDR
This article reviews some examples of repurposing of drugs in the treatment of TB, newer candidates for repurpose for which there is already preliminary evidence of activity and possible new options that merit further investigation. Expand
Evaluación de la actividad de diferentes antimicrobianos frente a Streptococcus pneumoniae provenientes de pacientes adultos con neumonía adquirida en la comunidad
TLDR
Parenteral (intravenous) penicillin and amoxicillin, independently of the way of administration, remain the antimicrobial β-lactams most suitable for the empirical treatment of pneumonia, while macrolides should be used with caution because of the high proportion of resistance. Expand
Comparative analysis of antibacterial potency of six fluoroquinolone antibiotics commonly prescribed in Uyo , Akwa Ibom State , Nigeria in the treatment of Salmonela typhi infections
Comparative analysis of antimicrobial potency of six common fluoroquinolone antibiotics was done. They were chosen based on their availability and affordability which includes: Ciprofloxacin,Expand
...
1
2
...

References

SHOWING 1-10 OF 93 REFERENCES
Treatment of community-acquired pneumonia, with special emphasis on gemifloxacin
  • S. Öncü
  • Therapeutics and Clinical Risk Management
  • 2007
Community-acquired pneumonia (CAP) is the cause of substantial morbidity, mortality, and resource utilization worldwide. When choosing an antimicrobial, effective treatment depends on proper patientExpand
Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.
TLDR
Data from comparative clinical trials suggest fluoroquinolone monotherapy is as efficacious as beta-lactam-macrolide combination therapy in the treatment of CAP patients and high-dose, short-course therapies may represent a significant advance in the management of CAP. Expand
Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia
TLDR
Oral moxifloxacin monotherapy was as effective as, and better tolerated than, optimal antibiotic strategy represented either by mono- or combination therapy (amoxicillin and/or clarithromycin) in community-acquired pneumonia management. Expand
Outpatient treatment of community-acquired pneumonia: evolving trends and a focus on fluoroquinolones.
  • A. Carrie, A. Kozyrskyj
  • Medicine
  • The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique
  • 2006
TLDR
The use of fluoroquinolones for the treatment of CAP is increasing, however less than 4% of the subjects receiving fluoroquolones met eligibility requirements according to treatment guidelines, and initiatives to increase the uptake of treatment guidelines appear warranted. Expand
Community-acquired pneumonia
TLDR
Important features and management issues of community-acquired pneumonia (CAP) that are especially relevant to immunocompetent adults in light of new information about cause, clinical course, diagnostic testing, treatment, and prevention are reviewed. Expand
Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.
TLDR
The patients in these studies were all classified as clinical cures despite persistence of the organism after antibiotic treatment, and as many as 40–70% of patients with culture-documented C. pneumoniae infection may remain seronegative by the microimmunofluorescence method, which is not standardized, and significant laboratory-to-laboratory variation in performance may occur. Expand
The safety profile of moxifloxacin and other fluoroquinolones in special patient populations
  • P. Iannini
  • Medicine
  • Current medical research and opinion
  • 2007
TLDR
Fluoroquinolones, are associated with rare, but clinically important, adverse events in special patient populations (including the elderly; those with hepatic, renal, or glycemic disorders; and those at risk for cardiovascular events); recognition of differences in the clinical efficacy and safety profiles of fluoroquolones inSpecial patient populations should lead to better antimicrobial agent selection. Expand
Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
  • A. Torres, J. Garau, +7 authors R. Read
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2008
TLDR
Monotherapy with sequential intravenous/oral moxifloxacin was noninferior to treatment with ceftriaxone plus levofloxACin combination therapy in patients with community-acquired pneumonia who required hospitalization. Expand
Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
TLDR
Intravenous/oral moxifloxacin therapy was efficacious and safe for hospitalized elderly patients with CAP, achieving > 90% cure in all severity and age subgroups, and was associated with faster clinical recovery than intravenous/ oral levofloxAcin therapy, with a comparable safety profile. Expand
Clinical Experience with Moxifloxacin in Patients with Respiratory Tract Infections
TLDR
Once-daily oral moxifloxacin 400 mg was shown to be safe and effective in this trial for the treatment of respiratory tract infections of suspected bacterial origin in the clinical practice setting. Expand
...
1
2
3
4
5
...